Comparative Pharmacology
Head-to-head clinical analysis: CARDIZEM CD versus ISOPTIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDIZEM CD versus ISOPTIN.
CARDIZEM CD vs ISOPTIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diltiazem is a calcium channel blocker that inhibits calcium ion influx across cardiac and vascular smooth muscle cell membranes, resulting in dilation of coronary arteries and peripheral arterioles, and decreased myocardial contractility and conduction velocity.
Verapamil inhibits calcium ion influx across cardiac and vascular smooth muscle cells, blocking L-type calcium channels, leading to vasodilation and reduced myocardial contractility and conduction velocity.
Hypertension: 180-360 mg once daily orally. Angina: 120-360 mg once daily orally. Maximum dose: 480 mg/day.
Initial dose: 80-120 mg orally three times daily; sustained-release: 120-240 mg orally once daily. IV: 5-10 mg slow IV push over 2 minutes, may repeat after 15-30 minutes. Maximum daily oral dose: 480 mg.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours (single dose), prolonged to 10-15 hours with multiple dosing or in elderly/hepatic impairment. Clinical context: Therapeutic steady-state achieved in 2-4 days.
Terminal elimination half-life: 4.5-12 hours (mean 8 hours); increases with hepatic impairment or cirrhosis
Renal: ~2-4% (unchanged), Hepatic metabolism to multiple metabolites; ~65% renal (metabolites), ~35% fecal/biliary. Total clearance: 5-7 mL/kg/min.
Renal (70% as metabolites, 3-5% unchanged); biliary/fecal (25%)
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker